Analytics

IV to Subcutaneous Conversion: The Data Behind the Switch, and What CMS's Final Negotiation Rule Changes

How to track IV to subcutaneous conversion as one patient on one molecule, and why CMS's November 2026 negotiation rule makes the product layer matter more.

Nov 20266 min readAnalytics

One patient, two routes, two sets of records

A patient on an intravenous biologic moves to the subcutaneous version of the same medicine. Clinically, it is the same therapy delivered a different way: minutes of injection in place of a chair in an infusion center. In many brand reports, though, the patient has stopped one product and started another. The IV line shows a discontinuation, the subcutaneous line shows a new patient start, and conversion is measured by comparing two totals that never shared a patient ID.

The reason is structural. The two versions often sit under different NDCs, different billing codes and sometimes different brand names. Their volume can arrive through different data: medical claims for a product given in a clinic, specialty pharmacy dispenses for one a patient takes at home. The site of care moves too, from a hospital outpatient department or infusion center to a physician office or the patient's home, and each of those sits at a different level of your account hierarchy.

On 5 November 2026, CMS issued its final rule for the Medicare Drug Price Negotiation Program, effective 5 December 2026 and governing the program from initial price applicability year 2029. It identifies a drug using all dosage forms and strengths with the same active moiety or ingredient and the same NDA or BLA holder, and it adds an exception for fixed combinations: where an added component, such as hyaluronidase, creates a new formulation and enables an alternative route of administration, CMS groups that product with the original (CMS fact sheet; Covington, 5 November 2026). As Pharmaceutical Commerce reported on 6 November 2026, if the original biologic is selected, that price would cover its hyaluronidase version from the same year. CMS framed this as a program integrity measure. Whatever the policy view, the practical point for commercial and data leaders is simple: if the rule treats both routes as one drug, your reporting needs to be able to do the same.

Four places route conversion data breaks

  • Two products, no shared patient

    IV volume from medical claims and subcutaneous volume from pharmacy dispenses carry different patient identifiers. Without linking, a converting patient is a stop on one line and a start on the other.

    • New patient starts inflated by switches
    • IV persistence understated
    • Conversion rate built from unrelated totals
  • Products that do not roll up

    The subcutaneous version is set up as its own product family, sometimes its own brand, with no molecule level above both. Brand, finance and forecasting each group the two routes differently.

    • Molecule totals rebuilt by hand
    • Route missing as a field
    • Billing codes mapped to only one version
  • Sites of care that move

    Infusion volume credited to a hospital outpatient department or infusion center reappears at a physician office or as home administration. If those sites are not in one HCO hierarchy, the account looks lost.

    • Account declines that are route shifts
    • Field credit moving between teams
    • Infusion center scorecards misread
  • Forecasts built on separate curves

    Long-range plans often model each route as its own product with its own price path. When pricing rules treat them as one drug, separate curves and separate net price assumptions need to be revisited.

    • Net price assumptions per route
    • Gross to net built on different channels
    • Scenarios that assume separate treatment

What good looks like

One molecule above both routes
One linked patient across claims and pharmacy data
Route change as its own event
Sites of care in one account hierarchy
Forecast and gross to net on the same grouping

How to put it in place

List every code for both routes

Pull every NDC and billing code for both versions that appears in claims, specialty pharmacy, distributor and hub data over the last two years, and check each maps to one molecule.

Agree what a conversion is

With brand, access, patient services and analytics, write down what counts as a route change, the window between the last IV dose and the first subcutaneous one, and how a return to IV is shown.

Link patients across data types

Link medical claims, pharmacy dispenses and hub records to one patient, and test the link on a sample of known conversions before trusting the rate.

Map the sites of care

Place every infusion center, outpatient department and office in one HCO hierarchy, and decide how field credit follows a patient whose site of care changes.

Restate and run side by side

Rebuild starts, persistence and conversion at molecule level and run them beside the current reports for a quarter, so leaders see what changed and why.

Questions leaders ask about IV to subcutaneous conversion data

What did CMS's November 2026 final rule say about new formulations?
The final rule, issued on 5 November 2026 and governing the program from initial price applicability year 2029, generally treats fixed combination drugs as distinct. It adds an exception: where an added component such as hyaluronidase creates a new formulation and enables an alternative route of administration, and the products share an active moiety or ingredient and an NDA or BLA holder, CMS groups them for identifying the drug. Read the rule and specialist legal analysis for how it applies to a specific product.
Why does our conversion rate look different in every report?
Usually because it is calculated from two product totals rather than from patients. When IV and subcutaneous volume come from different data and carry different patient IDs, switches, new starts and stops cannot be told apart. Linking patients and recording route change as an event gives one rate.
Why does an account look like it is declining when patients are converting?
The site of care often changes with the route. Volume that was credited to an infusion center or hospital outpatient department can move to a physician office or home. If those sites are not in one account hierarchy, the original account looks lost.
Should IV and subcutaneous versions be reported as separate brands?
Report both levels. Keep route as a field so each version can be seen on its own, but compute patients, starts and persistence at molecule level first, so a route change is never counted as a stop and a new start.
Who should own the molecule grouping?
Commercial operations or brand usually decides the grouping, analytics maintains the product table, and finance and pricing confirm it matches the grouping used for gross to net and forecasting. One named owner signs off each new code.

Check your route conversion data with us

Send us how your IV and subcutaneous volume reaches reporting today. We will show where switches read as stops, where sites of care fall out of the account view and what one molecule-level view would take. More on our work at specialty pharma analytics and automation.

Contact us

Part of our Pharma Commercial and Patient Analytics hub. Start with our specialty pharmacy analytics.

Talk to us

Is this a problem you are living with?

If any of the above sounds like your week, tell us which part. We will come back with what it would take to fix it.

  • A reply from a consultant, not a sales sequence
  • Usually within one working day
  • No obligation, and nothing to sit through

We reply from [email protected], usually within one working day. We do not add you to a mailing list.